# Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

> **NCT01613118** · PHASE2 · COMPLETED · sponsor: **Travere Therapeutics, Inc.** · enrollment: 109 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** RE-021 (Sparsentan)
- **DRUG:** Irbesartan

## Key facts

- **NCT ID:** NCT01613118
- **Lead sponsor:** Travere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-06
- **Final completion:** 2024-03-25
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01613118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01613118, "Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01613118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*